Phase 2RecruitingAge-related condition

Placebo-Controlled Trial of Urolithin A Supplementation in Men With Prostate Cancer Undergoing Radical Prostatectomy, URO-PRO Trial

A Phase 2 Placebo-Controlled Trial of Urolithin A Supplementation in Men With Prostate Cancer Undergoing Radical Prostatectomy

Sponsor
National Cancer Institute (NCI) (NIH)
Enrollment
90 planned
Conditions
Prostate Adenocarcinoma
Interventions
Biopsy Procedure; Biospecimen Collection; Placebo Administration; Urolithin A Supplement
Ages
adults, older adults
Registry
NCT06022822

Full record on ClinicalTrials.gov

From the registry

This phase II randomized control trial assesses the effect of Urolithin A (Uro-A) supplementation compared to placebo in men with biopsy-confirmed prostate cancer undergoing radical prostatectomy (RP) progressive disease. A total of 90 men will be accrued and randomized 1:1 to receive a 1000 mg daily dose of Uro-A in two 250 mg capsules PO BID or two placebo capsules BID daily for 3 to 6 weeks prior to RP. The primary endpoint is to determine the effect of Uro-A on decreasing prostate tumor tissue oxidative stress (measured by 8-OHdG) compared to placebo.

Primary outcomes

  • Percent positive change in 8-OHdG

History

  1. Study completion expected

  2. Primary completion expected

  3. Last registry update

  4. Started

  5. Registered